Key result
Polyherbal formulation attenuates diabetic cardiac injury by curbing oxidative stress and inflammation in rats.
Why the study?
The effect of a polyherbal formulation on inflammation and oxidative stress in diabetic cardiomyopathy induced in rats was evaluated to explore potential therapeutic benefits.
Does a polyherbal formulation ameliorate inflammation and oxidative stress in a rat model of diabetic cardiomyopathy?
Does a polyherbal formulation ameliorate inflammation and oxidative stress in a rat model of diabetic cardiomyopathy?
A polyherbal formulation ameliorated hyperglycemia-mediated inflammation and oxidative stress in a rat model of diabetic cardiomyopathy via the NF-κB/Nrf-2/HO-1 pathway.
Does not support clinical use of PHF in diabetic cardiomyopathy; leaves open translation of rat findings to human trials.
The present study was intended to evaluate the effect of polyherbal formulation (PHF) made with 3 nutraceuticals, such as Piper nigrum, Terminalia paniculata, and Bauhinia purpurea on inflammation and oxidative stress in diabetic cardiomyopathy (DCM), which is induced by streptozotocin and nicotinamide administration in rats. We supplemented DCM rats with PHF (250 and 500 mg/kg/BW) for 45 days and evaluated their effects on oxidative stress markers, proinflammatory cytokines, and messenger RNA expressions of the nuclear factor erythroid 2-related factor-2 (Nrf-2) and its linked genes [heme oxygenase-1 (HO-1), superoxide dismutase, catalase] along with inflammatory genes [tumour necrosis factor α and nuclear factor kappa B (NF-κB)]. Our study demonstrated that PHF successfully attenuated inflammation and oxidative stress via messenger RNA upregulation of Nrf-2, HO-1, superoxide dismutase, and catalase and concomitantly with downregulation of tumour necrosis factor α and NF-κB. Conversely, PHF also protected hyperglycemia-mediated cardiac damage, which was confirmed with histopathological and scanning electron microscopy analysis. In conclusion, our results suggested that PHF successfully ameliorated hyperglycemia-mediated inflammation and oxidative stress via regulation of NF-κB/Nrf-2/HO-1 pathway. Therefore, these results recommend that PHF may be a prospective therapeutic agent for DCM.
No takes yet. Share an insight, caveat, or question.
A 2021 study studied Diabetic cardiomyopathy. Polyherbal formulation (PHF) was evaluated on Inflammation and oxidative stress markers, and mRNA expressions of Nrf-2, HO-1, SOD, catalase, TNF-α, and NF-κB. Polyherbal formulation attenuated inflammation and oxidative stress via the NF-κB/Nrf-2/HO-1 pathway and protected against hyperglycemia-mediated cardiac damage in diabetic rats.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: